{"created":"2023-06-19T11:22:27.436247+00:00","id":63,"links":{},"metadata":{"_buckets":{"deposit":"e7dab36f-1534-4cfa-b862-cdb5ab8d8173"},"_deposit":{"created_by":12,"id":"63","owners":[12],"pid":{"revision_id":0,"type":"depid","value":"63"},"status":"published"},"_oai":{"id":"oai:jichi-ir.repo.nii.ac.jp:00000063","sets":["14:18"]},"author_link":["448","449","450","451","452","453","454","455","456","457","458"],"control_number":"63","item_2_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2014-03","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"31","bibliographicPageStart":"23","bibliographicVolumeNumber":"36","bibliographic_titles":[{"bibliographic_title":"自治医科大学紀要"},{"bibliographic_title":"Jichi Medical University Journal","bibliographic_titleLang":"en"}]}]},"item_2_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"CD28を含むCD19特異的第二世代キメラ抗原受容体（CD19-CAR）による養子免疫遺伝子療法はＢ細胞腫瘍に対する有望な治療法である。本研究において我々は，CD19-CARに加えIL-21を遺伝子導入したＴ細胞を作製し，CD19-CAR単独導入Ｔ細胞に比し抗腫瘍効果の増強が得られるかを検討した。まず健常者由来の末梢血リンパ球を活性化し，CD19-CAR+IL-21共発現またはCD19-CAR発現レトロウイルスベクターを用いて遺伝子導入した。導入遺伝子の発現はいずれも良好であった。両細胞は同様の増殖を示し，CD19-CAR+IL-21導入細胞でのみIL-21シグナリングの代替マーカーであるSTAT3のリン酸化を認めた。両細胞は表面マーカー上主にCentral memoryあるいはeffector memoryの形質を示し，CD19陽性Ｂ細胞株であるRajiに対して細胞傷害性を示し，CD19刺激によりIFN-γを産生した。Rag2-/-γc-/-免疫不全マウスを用いた動物実験では，両細胞はいずれもRajiの増殖を抑制した。IL-21は我々のＢリンパ腫モデルでは抗腫瘍効果を修飾せず，CD19-CAR導入Ｔ細胞は単独で十分な抗腫瘍効果を発揮する可能性が示された。","subitem_description_type":"Abstract"}]},"item_2_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"自治医科大学"}]},"item_2_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1881-252Ｘ","subitem_source_identifier_type":"PISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Yamamoto, Chihiro","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tsukahara, Tomonori","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ohmine, Ken","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Teruya, Takeshi","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ido, Hiroyuki","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Uchibori, Ryosuke","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Urabe, Masashi","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Mizukami, Hiroaki","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kume, Akihiro","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakamura, Masataka","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ozawa, Keiya","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2014-05-28"}],"displaytype":"detail","filename":"p23-31.pdf","filesize":[{"value":"587.1 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"D:\\第36巻Web\\jichi medical 36\\36pdf-link\\p23-31.pdf","url":"https://jichi-ir.repo.nii.ac.jp/record/63/files/p23-31.pdf"},"version_id":"4e8d497c-ef2c-4fc0-bdd6-ba4ce4975c04"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"B cell lymphoma","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"chimeric antigen receptor","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"engineered T cell therapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"IL-21","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"IL-21 is not necessary for anti-lymphoma effects of T cells expressing second-generation CD19-specific chimeric antigen receptors in a xenograft mouse model.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"IL-21 is not necessary for anti-lymphoma effects of T cells expressing second-generation CD19-specific chimeric antigen receptors in a xenograft mouse model.","subitem_title_language":"en"}]},"item_type_id":"2","owner":"12","path":["18"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2014-05-28"},"publish_date":"2014-05-28","publish_status":"0","recid":"63","relation_version_is_last":true,"title":["IL-21 is not necessary for anti-lymphoma effects of T cells expressing second-generation CD19-specific chimeric antigen receptors in a xenograft mouse model."],"weko_creator_id":"12","weko_shared_id":-1},"updated":"2023-08-28T04:00:20.347167+00:00"}